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Abstract
Background: Treatment for patients with breast cancer (BC) is guided by human epidermal growth factor receptor 2
(HER2) status. The patient’s HER2 status is assessed using US Food and Drug Administration-approved in vitro
diagnostic (IVD) immunohistochemical (IHC) tests and laboratory-developed IVD tests. We analysed HER2 testing
accuracy using data from the Nordic Immunohistochemistry Quality Control (NordiQC) HER2 IHC programme; results
were used in an economic BC treatment model.
Methods: Data were obtained from NordiQC HER2 BC surveys performed from 2008 to 2012. False-negative (FN) and
false-positive (FP) rates for approved and laboratory-developed IVDs were used to estimate direct costs, loss of survival,
productivity benefit and quality-adjusted life-years. In the absence of consistent and accessible clinical and economic
data from countries participating in the NordiQC programme, United States productivity data, healthcare costs and
patient numbers were used as a surrogate in order to estimate the potential impact of selecting an approved or
laboratory-developed IVDs.
Results: In total, 1703 tests were performed. Pooled FN rates were 11 % for approved IVDs and 25 % for laboratory-
developed IVDs; FP rates were 0 % and 5 %, respectively. Using these FP and FN rates in the economic model and
applying them to the United States BC population, approved IVD tests would result in better clinical outcomes, i.e.,
better survival and fewer disease recurrences/progressions, and lower costs, i.e., total direct costs and lost productivity,
versus laboratory-developed IVD tests. Every $1 saved by laboratories by using cheaper reagents could potentially
result in approximately $6 additional costs to the healthcare system.
Conclusions: The results of this analysis suggest that incorrect HER2 test results have far-reaching clinical and
economic consequences.
Background
Breast cancer is the most commonly diagnosed malig-
nancy in women worldwide and the leading cause of
cancer death in developed and developing countries [1].
Breast cancer accounted for an estimated 1.67 million
new cancer cases worldwide and 522 000 of all cancer
deaths in 2012 [2].
The management of patients with breast cancer is
complex and depends on a combination of factors.
These include disease stage, age and menopausal status,
the oestrogen receptor (ER) and progesterone receptor
(PgR) status of the tumour, its proliferative capacity and
the human epidermal growth factor receptor 2 (HER2)
expression status [3].
Approximately 15–20 % of women with breast cancer
have tumours that overexpress HER2 [4]. HER2 positiv-
ity is associated with aggressive disease and poor prog-
nosis [5, 6], but the development of HER2-targeted
therapies in recent years has significantly improved out-
comes for patients with early stage and metastatic
HER2-positive disease [7–9].
Correct histopathological assessment is the key to op-
timal treatment selection for patients with breast cancer.
Tumour classification is based on morphological
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features and molecular profiles. Correct identification of
tumour receptor status (ER/PgR for endocrine therapy
and HER2 status for targeted therapy) is a prerequisite
for treatment planning. In order to qualify for HER2-
targeted therapy, the patient must have a HER2-positive
tumour. This can be determined by measuring HER2
protein levels using immunohistochemistry (IHC) and/or
by measuring HER2 gene amplification by in situ
hybridization (ISH). Current guidelines recommend using
either IHC or ISH to assess tumour HER2 status for all
patients with breast cancer. Both tests are used, in case an
equivocal result is obtained with the first test [3, 10].
The reliability and accuracy of HER2 IHC assays used
in clinical practice has improved since the publication
and endorsement of procedural guidelines [11, 12].
Many countries now have proficiency programmes for in
vitro diagnostic (IVD) HER2 testing to ensure the re-
quired accuracy standards are maintained. However, not
all IVD test systems perform equally. Performance de-
pends on the quality of assay reagents and the reliability
of test protocols. Some IVD tests are available as indus-
trially produced and packaged products that are vali-
dated, approved and regulated by the US Food and Drug
Administration (FDA). Other IVD tests are created by
the pathology laboratories conducting the test, which as-
semble them from individually available components
(often referred to as laboratory-developed tests). When
used properly, both the approved and laboratory-
developed IVDs can perform equally well; conversely,
both classes of IVD have the potential to fail and pro-
duce incorrect results. Approximately 67 % of HER2
tests performed by participants in the Nordic Immuno-
histochemistry Quality Control (NordiQC) programme
were approved and validated IVD tests, while the remaining
33 % of tests were laboratory-developed IVD tests
(NordiQC 2008–2012). Similar proportions (71 % approved
IVD tests and 29 % laboratory-developed IVD tests) have
been reported for participants in the UK National External
Quality Assessment Service (NEQAS) Breast Screening
programme [13]. In some countries, the proportion of tests
performed using approved IVD tests may be lower. For
example, in a Belgian survey of HER2 testing, only 4 of 34
laboratories used an approved IVD testing kit [14].
The techniques and technologies underlying HER2
testing are not always made clear to oncologists because
samples are processed independently in pathology la-
boratories; however, the oncologist needs a categorical
answer regarding the patient’s HER2 status. The decision
to treat a patient with HER2-targeted therapy is based
largely on the reported result of the IVD test, which —
if incorrect—may have significant consequences for both
the patient and the society.
The aim of this study was to compare the socioeco-
nomic consequences of the accuracy of different HER2
IVD testing procedures using data from a real-world
testing/proficiency programme run by the NordiQC
group. In this report we describe the reliability of results
obtained from approved and laboratory-developed IVD
IHC tests assessed by the NordiQC group and consider
the potential clinical, economic and socioeconomic im-
pact of inaccurate HER2 test results and subsequent
treatment for patients with breast cancer.
Methods
Data sources
HER2 IHC testing data were collected and provided by
the NordiQC organisation. These data were used in an
economic model of breast cancer that was developed at
Ventana Medical Systems, Inc./Roche.
NordiQC programme
Pathology laboratories in over 40 countries that perform
IHC tests are invited to participate in a quality assessment
of their immunostaining procedures as part of the
NordiQC Breast Cancer HER2 IHC programme (Fig. 1).
There are two shipments (or runs) per year, each of which
contains a 5-core microarray slide of breast cancer cores
with varying predefined HER2 expression (0/1+/2+/3+)
and amplification levels (both amplified and unamplified
for 2+ cancer cores) as verified by using two IHC FDA/
CE-IVD approved assays (HercepTest™, Dako, Glostrup,
Denmark; PATHWAY®, Ventana Medical Systems, Inc.,
Tucson, AZ, USA) in NordiQC reference laboratories, and
using the HER2 fluorescence in situ hybridisation (FISH)
pharmDX™ Kit (Dako). Laboratories use their own stand-
ard protocol to stain slides and return them for central as-
sessment by the NordiQC assessor group, which is blinded
to laboratory identity and assay used. False negative (FN)
and false positive (FP) definitions and values obtained from
the NordiQC programme were used. In brief, an FN reac-
tion was defined as a HER2 staining reaction which was
scored by the assessors as 0/1+ in a HER2 gene amplified
tumour with a 2+/3+ HER2 expression in the reference la-
boratories. An FP reaction was defined as a HER2 staining
reaction which was scored by the assessors as 3+ in a
HER2 gene non-amplified tumour with a 0/1+/2+ HER2
expression in the reference laboratories.
Data from the NordiQC website for runs B6–14 were
used in this analysis [15].
The study involved the use of data obtained from a
quality assurance program based on anonymous human
biological material collected in accordance with legisla-
tion at the site of collection; as a result, no ethics com-
mittee approvals were needed.
Cost calculator/modelling tool
For the approved and laboratory-developed IVD tests,
the possible consequences of FP and FN HER2 test
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outcomes were considered in relation to direct medical
costs, life expectancy, quality of life and loss of productiv-
ity in patients with early stage breast cancer (EBC; stage II
and III disease) and receiving systemic treatment, as well
as in those with metastatic breast cancer (MBC; stage IV
disease) as detailed below. When considering the differen-
tial cost of HER2 tests, reagent costs for approved and
laboratory-developed IVD tests used in the NordiQC la-
boratories were assumed at $45 and $10, respectively
[NordiQC programme, personal communication].
Survival calculations for patients with EBC were based
on the results of a pooled analysis of survival among pa-
tients in the National Surgical Adjuvant Breast and
Bowel Project B31 and the North Central Cancer Treat-
ment Group trial N9831 studies [16]. For patients with
MBC, survival calculations were based on the phase III
H0648g study by Slamon and colleagues [7]. The num-
ber of patients who avoided disease progression because
of the lower FN test rate with an approved IVD in com-
parison with a laboratory-developed IVD test was calcu-
lated based on disease-free survival data from the
H0648g MBC trial [7].
The number of quality-adjusted life-years (QALYs) lost
as a result of a patient not receiving trastuzumab was
also calculated. Lost productivity was based on the loss
of QALYs, assuming an interaction between QALYs and
productivity, both of which are influenced by health
state and deteriorate in parallel [17].
A cost calculator was developed to assess the direct fi-
nancial impact of FN and FP tests. A societal perspective
was adopted and US costs were used because of the
homogeneity of pricing in the US healthcare system
compared with the variety of systems in place in the EU.
Costs were adjusted to 2014 values using an annual in-
flation rate of 3 % [18]. For patients with EBC, a 5-year
time horizon was used to generate an annualised 1-year
time horizon; a 1-year time horizon was used for pa-
tients with MBC.
All results were extrapolated to the estimated numbers
of patients receiving systemic treatment for breast can-
cer in the US to correspond with the use of US eco-
nomic data and weighted according to the observed
prevalence of patients with IHC 0/1+/2+ unamplified
carcinomas, 2+ amplified carcinomas and 3+ carcinomas
(80 %, 4 % and 16 %, respectively) [19]. This extrapola-
tion was performed to gain an effect of the potential
costs associated with selection of the IVD test and was
not intended to suggest that such costs might be saved
or accrued in the US.
Results
Key features of the NordiQC HER2 testing programme
are shown in Fig. 1. Sample test results are shown in
Fig. 2, highlighting accurate and inaccurate staining of
the samples.
IHC test results
NordiQC HER2 testing data obtained from runs B6 to
B14 were pooled [15]. The overall FP rate was 0 % (0 of
1145 samples) for the approved IVD tests and 5 % (28 of
558 samples) for the laboratory-developed IVD tests. FN
rates were 11 % (127 of 1145 samples) for the approved
IVD tests and 25 % (141 of 558 samples) for the
laboratory-developed IVD tests (Table 1).
Impact of inaccurate results on patient outcomes
Calculations for patient outcomes were based on the es-
timated 232 340 patients with invasive breast cancer in
the USA in 2013 [20], 132 433 (57 %) of whom are
Cores validated to have same HER2 expression
and gene status; obtained from different patients




• Borderline (low signal-to-noise ratio)
• Poor (false negative or false positive staining)
Results pooled and published every 6 months
1 slide, 5 tissue samples:
1. Ductal carcinoma (IHC 0/1+; FISH unamplified)
2. Ductal carcinoma (IHC 0/1+; FISH unamplified)
3. Lobular carcinoma (IHC 1+/2+; FISH unamplified)
4. Ductal carcinoma (IHC 2+/3+; FISH amplified)





Fig. 1 NordiQC HER2 assessment scheme. NordiQC criteria for assessing
a HER2 stain as optimal are clear and unequivocal staining reactions
corresponding to the 0/1+/2+/3+ IHC scores (as specified by current
ASCO/CAP scoring criteria [ASCO/CAP 2007 [10]) obtained in the
reference laboratories. A stain is assessed as good if a HER2-amplified 3+
carcinoma or a HER2-unamplified 0/1+ carcinoma reveals a 2+ reaction.
A stain is assessed as borderline if the signal-to-noise ratio is low, for
example in cases of moderate cytoplasmic reaction, excessive
counterstain or excessive retrieval hampering interpretation. A stain is
assessed as poor in case of a FN reaction (for example a 3+ carcinoma or
a 2+ carcinoma with HER2 gene amplification that reveals a 0 or 1+
reaction) or a FP stain where a 0/1+ or 2+ carcinoma without HER2 gene
amplification reveals a 3+ reaction. The inclusion of 2+ cores with and
without HER2 gene amplification is considered essential to evaluate the
IHC HER2 performance and the robustness of the pathology laboratories’
protocols, as 2+ cores are more likely to reveal FN or FP staining
reactions than 3+ or 0/1+ cores, respectively. ASCO, American Society of
Clinical Oncology; CAP, College of American Pathologists; IHC,
immunohistochemistry; NordiQC; Nordic Immunohistochemistry Quality
Control Group
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estimated to have EBC requiring systemic therapy and
16 263 (7 %) of whom have MBC; the remainder have
EBC that does not require systemic therapy.
For patients with EBC, an FN HER2 test was calcu-
lated to result in a difference of 3.9 % per annum in add-
itional life expectancy that might have been achieved if
the patient had received trastuzumab, based on cumula-
tive progression over 5 years in 18.2 % of patients with
EBC [16]. Using the NordiQC FP and FN rates, the esti-
mated loss of survival per patient would be 0.0045 years
for the approved IVD tests and 0.0102 years for the
laboratory-developed IVD tests. Extrapolation to the US
breast cancer population over a 1-year time horizon would
give a total missed gain in life expectancy of 177 and
403 years, respectively, for the approved and laboratory-
developed IVD tests, representing a difference of 226 years
(Fig. 3a). A similar calculation was performed for patients
with MBC, based on the 4.8 months’ additional life ex-
pectancy provided by trastuzumab (median overall sur-
vival 25.1 months for chemotherapy + trastuzumab vs
20.3 months for chemotherapy alone) [7]. The estimated
total missed gain in life expectancy would be 215 years for
the approved IVD tests and 488 years for the laboratory-
developed IVD tests, representing a potential difference of
273 years for patients with MBC (Fig. 3a).
The estimated effect of an FN HER2 test on the num-
ber of patients with disease recurrence or progression
was also calculated. Based on the estimated incidence of
disease recurrence in 3.9 % of patients with EBC [16],
170 EBC patients tested with an approved IVD HER2
test and 387 tested with a laboratory-developed IVD
HER2 test would have recurrent disease as a result of
Fig. 2 Staining reactions submitted to NordiQC based on optimal and insufficient protocols. HER2 stains of four breast carcinomas (a–d) in three
laboratories (1–3). The stains from laboratory 1 (upper row) were assessed as optimal, while stains from laboratory 2 (middle row) were too weak,
and from laboratory 3 (lower row) were over-stained; both sets were assessed as poor. 1a) In tumour a, >30 % of the neoplastic cells show an
expected strong and complete membranous staining, corresponding to score 3+; FISH test showed amplification, HER2/CEN17 ratio >6. 1b) In
tumour b, >10 % of neoplastic cells show an expected moderate complete membranous staining corresponding to score 2+; tumour b is
amplified, HER2/CEN17 ratio 2.4–2.9. 1c) Tumour c stains as tumour b, but is unamplified, HER2/CEN17 ratio 1.3–1.6; 1d) In tumour d, no staining is
identified; the tumour is unamplified, HER2/CEN17 ratio 1.1–1.4. 2a) Tumour a shows a 2+ reaction that would be reflexed to FISH test; 2b-d)
Tumours b, c and d show a 0/1+ reaction. As the amplified tumour b would not be reflexed to FISH test, the patient would erroneously not be
offered trastuzumab treatment. 3a-d) Widespread cytoplasmic reaction is seen in all four tumours. The stain of unamplified tumour c might be
interpreted as a 3+; the tumour therefore would not be not reflexed to FISH test and the patient would erroneously be offered trastuzumab
treatment. FISH, fluorescence in situ hybridisation
Table 1 FP and FN rates for immunohistochemical testing as recorded by the NordiQC programme
Approved IVD, n (%) (n = 1145) Laboratory-developed IVD, n (%) (n = 558)
Data source FN FP FN FP
NordiQC runs B6–14a 127 (11) 0 141 (25) 28 (5)
FN false negative, FP false positive, IVD in vitro diagnostic, NordiQC Nordic Immunohistochemistry Quality Control Group
aNordiQC IHC quality-control organisation, B6–14 runs [15]. Laboratories were provided with samples that were IHC 0, 1+, 2+ and 3+
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the FN test result. In total, an estimated 217 recurrences
in patients with EBC could be avoided annually through
the use of approved versus laboratory-developed IVD
HER2 tests (Fig. 3b). In patients with MBC, based on an
estimated difference in progression-free survival after
1 year of 16 % between patients treated with trastuzu-
mab and those who did not receive trastuzumab [7], 86
patients tested with an approved IVD and 195 tested
with a laboratory-developed IVD HER2 test would have
progressive disease as a result of the FN result. This is
the equivalent of 109 progressions in patients with MBC
that could be avoided each year by using an approved in-
stead of a laboratory-developed IVD test.
In patients with EBC, false test results would result in
a missed gain in QALYs of 0.0038 for patients tested
with an approved IVD compared with 0.0086 QALYs for
those tested with a laboratory-developed IVD. When ex-
trapolated to the US population, assuming a time hori-
zon of 1 year and weighting according to the prevalence
of IHC categories, this led to an estimated 149.7 missed
QALYs in patients tested with an approved IVD, vs
342.3 missed QALYs in those tested with a laboratory-
developed IVD, a difference of 192.5 missed QALYs in
favour of the approved IVD test. In patients with MBC,
the corresponding values would be 0.0024 QALYs and
0.0054 QALYs, resulting in a potential difference be-
tween approved IVD tests and laboratory-developed IVD
tests of 15 QALYs when applied to the US breast cancer
population (Fig. 3c).
Economic cost of inaccurate results
As shown in Table 2, the estimated total direct cost of
an FP or FN HER2 test for a patient with EBC that could
be avoided each year by using an approved versus a
laboratory-developed IVD HER2 test was $364 for the
approved IVD tests and $1394 for the laboratory-
developed IVD tests. When extrapolated to the US
population with EBC and weighted according to the
prevalence of the IHC categories to gain an estimate of
the potential effect of use of an approved or a
laboratory-developed IVD, this translated into potential
total direct costs of $14 447 666 for approved IVD tests
and $55 1377 720 for the laboratory-developed IVD
tests. Corresponding values for MBC were $859 446 and
















































































Fig. 3 Impact of HER2 testing. a Missed gain in life expectancy; b
avoidable recurrences and progressions; and c QALYs missed in
patients with early and metastatic breast cancer based on US
patient numbers and NordiQC FN and FP results; weighted
according to the estimated prevalence of IHC 2+ cases (20 %). EBC,
early breast cancer; FN, false negative; FP, false positive; IHC,
immunohistochemistry; IVD, in vitro diagnostic; MBC, metastatic
breast cancer; QALY, quality-adjusted life-year
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IVD rather than a laboratory-developed IVD test would
result in potential savings of $40 930 054 for EBC and
$5 133 025 for MBC. Therefore, use of approved rather
than laboratory-developed IVD tests could result in a
saving of approximately $46 million.
In terms of lost productivity, FN and FP HER2 test re-
sults associated with approved versus laboratory-developed
IVD tests would result in a reduction in lost productivity
estimated at $4 244 968 in patients with EBC, assuming
a time horizon of 5 years, annualised to give a 1-year
time horizon. In patients with MBC, the difference be-
tween approved and laboratory-developed IVD tests
would be $330 627.
Despite the more expensive initial outlay for the ap-
proved rather than for laboratory-developed IVD tests,
the approved IVD tests could still potentially generate
considerable savings. Considering a differential cost, in
terms of reagents alone, of approximately $35 between
the approved and laboratory-developed IVD tests used
in the NordiQC laboratories, reagents for the primary
testing of US breast cancer patients with an approved
IVD could potentially cost approximately $10 million
per annum, with a further $15 million associated with
total additional direct costs resulting from FN and FP
test results. In contrast, reagent costs for primary testing
with laboratory-developed IVD tests would potentially
result in only approximately $2.5 million per annum in
testing costs, but total additional direct costs resulting
from FN and FP test results could amount to $60 mil-
lion. The ratio of reagent:direct costs for the laboratory-
developed IVDs ($62.5 million) and approved IVDs ($25
million) is therefore estimated at 2.5:1.
Discussion
HER2 expression in breast cancer tissue is indicative of
an aggressive pathology. HER2 expression is therefore
considered a marker of poor prognosis and results from
clinical trials have demonstrated a significant benefit for
HER2-targeted therapy in patients with HER2-positive
EBC [8] and MBC [7]. Therapeutic inhibition of the
HER2 pathway has the potential to counteract the prog-
nostic risk associated with HER2 positivity. Currently,
four HER2-directed agents are available for use in the
treatment of HER2-positive breast cancer: the antibodies
trastuzumab, pertuzumab and trastuzumab emtansine,
and the tyrosine kinase inhibitor lapatinib. However,
the benefit of HER2-targeted therapies is restricted to
patients with HER2 gene amplification or protein over-
expression. All HER2-directed therapies can cause se-
vere adverse events and have a heightened risk of
causing significant patient harm when used in error.
Therefore, they must only be administered to eligible
patients most likely to respond. HER2-targeting agents
are expensive medicines and are only cost-effective if
used correctly. Therefore, accurate HER2 testing and
HER2 status determination is fundamental to the
Table 2 Early stage breast cancer: economic costs of inaccurate HER2 immunohistochemical test results. Based on FN and FP test
results (Nordic Immunohistochemistry Quality Control Group data), US treatment costs, US patient numbers and US productivity
data; weighted according to the estimated prevalence of immunohistochemistry scores
Early stage breast cancer
Cost, US $ Approved IVD Laboratory-developed IVD Difference
Direct cost/patient 364 1394 1030
Total direct costsa 14 447 666 55 377 720 40 930 054
Cost of lost productivity/patientb 83 190 107
Total cost of lost productivityc 3 301 263 7 546 231 4 244 968
IVD in vitro diagnostic
aCosts corrected for the prevalence of IHC 2+ tumours [19]. bProductivity loss per year per patient undergoing a HER2 test. cCost for the annual number of new
patients undergoing a HER2 test and receiving systemic treatment in the USA
Table 3 Metastatic breast cancer: economic cost of inaccurate HER2 immunohistochemical test results. Based on FN and FP test
results (Nordic Immunohistochemistry Quality Control Group data), US treatment costs, US patient numbers and US productivity
data; weighted according to the estimated prevalence of immunohistochemistry
Metastatic breast cancer
Outcome, US $ Approved IVD Laboratory-developed IVD Difference
Direct cost/patient 176 1228 1052
Total direct costsa 859 446 5 992 471 5 133 025
Cost of lost productivity/patientb 52 120 68
Total cost of lost productivityc 255 594 586 221 330 627
IVD in vitro diagnostic
aCosts corrected for the prevalence of IHC 2+ tumours [19]. bProductivity loss per year per patient undergoing a HER2 test. cCost for the annual number of new
patients undergoing a HER2 test and receiving systemic treatment in the USA
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success, safety and cost-effectiveness of breast cancer
treatment programmes.
Analysis of HER2 status may be requested by oncolo-
gists who may have limited knowledge of the reliability
and accuracy of the currently available HER2 testing
methodologies used in the pathology laboratory. The on-
cologist must rely on the pathology report as the basis
for selecting subsequent therapy for the patient, whose
treatment outcome and safety ultimately depend on the
result of this test.
Public regulations and controls on the accuracy of
HER2 IVD tests are not uniformly available or executed.
HER2 immunostaining must be carefully calibrated in
order to define with a high degree of reliability which
carcinomas are HER2 amplified. The NordiQC quality
assessment programme for HER2 is based on a compos-
ition of five samples with HER2 expression of 0 to 3+ as
defined in reference laboratories. Two of the samples are
IHC equivocal (2+), one amplified and one unamplified,
the staining reactions of which are particularly important
for correct calibration. All laboratories examine the same
five highly and robustly characterised tumour specimens
using their own standard procedures, providing NordiQC
with a good understanding of the quality of their
staining procedure. When a HER2-amplified tumour
with an expected 2+ IHC reaction is under-stained,
giving a 1+ reaction, the tumour will be considered un-
amplified and not reflexed to FISH. Likewise, when a
HER2-unamplified tumour with an expected 2+ IHC re-
action is over-stained, giving a 3+ reaction, the tumour
will be considered amplified and in most cases not re-
flexed to FISH. Thus, the inclusion of IHC-equivocal tu-
mours is essential to reveal insufficient staining
reactions, which may not be identified if only tumours
with 0 and 3+ HER2 expression are included, as is the
case in other programmes. As there is a degree of flux in
participating laboratories and some additional variation
in assays used even by long-term participants, there is
inevitably some variation in results over time [15]. Nine
consecutive runs, B6–B14, were chosen as they were
based on the same composition of tumours. Run B6 was
the first to include two IHC-ambiguous (2+) cancers,
one being amplified and one unamplified; run B14 was
the last before the ASCO/CAP guidelines were changed.
As a result of the revisions to the guidelines, some tu-
mours previously classified as 1+ are now classified as 2+,
which reduced the proportion of FN cases while in-
creasing the load of FISH tests. Examination of this
series of runs, all of which were performed under con-
sistent conditions and in line with the same guidelines,
has allowed us to gain the greatest insight into and most
reliable assessment of the quality of HER2 IHC testing
among laboratories participating in the NordiQC
programme.
In Europe, besides a general quality/safety label for
medical devices, no further discrimination of HER2 test
systems exists. In the USA, however, the FDA strictly
oversees IVD tests that are used for any treatment deci-
sions. For a variety of reasons, not least of which is the
high development cost of such an approved test that in-
volves extensive independent validation and proof of
clinical utility from clinical trials, few diagnostic tests
have been approved by the FDA. Approved IVD tests
sell at a higher price than laboratory-developed IVD
tests. Many laboratories are urged to be as cost-saving as
possible and prefer to run laboratory-developed test sys-
tems because of the lower reagent costs involved. Our
analysis was undertaken to raise awareness of the poten-
tial clinical, economic and socioeconomic differences be-
tween FDA-approved and other available assays and to
provide oncologists with the information necessary to
discuss with pathologists which tests to use for max-
imum patient benefit and safety. Moreover, it is import-
ant to demonstrate to payers that an accurate HER2
result has a greater impact on costs than simply the up-
front cost of the test.
To the best of our knowledge, this is the first analysis
to calculate FN and FP rates for approved and
laboratory-developed IVD tests using ‘real-world’ HER2
results from a proficiency testing programme. Analysis
of the NordiQC test programme provided FN and FP
rates of 25 % and 5 %, respectively, for the laboratory-
developed IVD tests and 11 % and 0 %, respectively, for
the approved IVD tests. The large majority of inaccurate
test results resulted from the failure to correctly identify
IHC 2+ samples. Notably, almost all (83 %) of these in-
correct results falsely identified samples as being HER2
negative, which could result in a HER2-positive patient
(positivity to be confirmed by reflex ISH to determine
HER2 amplification status) not receiving anti-HER2
treatment. Our findings are supported by similar results
obtained by the UK NEQAS IHC Breast Screening
programme: based on runs 100, 101 and 102, laborator-
ies using approved IVD kits had pass rates of 91 %, 88 %
and 94 %, compared with pass rates of 23 %, 47 % and
43 % for laboratory-developed IVD tests [13]. In a Ger-
man ring study of breast cancer testing procedures, dis-
cordant results with a high percentage of FN scorings
were encountered in HER2 equivocal (IHC 2+) cases
compared with IHC 0/1+ and 3+ cases, with only 41 %
of participants scoring these cases correctly [21]. This
underlines the importance of including 2+ cases in the
HER2 challenges.
Based on the economic model, which used US epi-
demiological and economic data in the absence of consist-
ent, publicly available data for the countries participating
in the NordiQC programme, using approved rather than
laboratory-developed IVD HER2 tests could result in a
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saving of $46 million per year, largely as a consequence of
the correct use of trastuzumab leading to avoidance of
treatment costs associated with disease recurrence and
progression. Although reagent costs are lower for the
laboratory-developed IVD tests, the approved IVD tests
are still cost saving when a broader perspective is taken, as
the overall cost of using a laboratory-developed system is
approximately 2.5 times greater than the overall cost of
approved IVD tests. For each $1 saved by the pathology
laboratory by using cheaper reagents, the healthcare sys-
tem is potentially burdened with approximately $6 in add-
itional costs. Extrapolation of these results to the EU
breast cancer population, where the numbers of patients
with EBC and MBC are greater than the numbers used in
our analysis, suggests that the potential for savings is even
greater, particularly if other HER2-overexpressing cancers
are considered [22].
Some potential limitations of this analysis should be
considered. The NordiQC programme uses only five
tissue samples. If any of these are unusual in a way that
affects the performance of approved and laboratory-
developed assays differentially, this could have created
bias in the comparison. We can think of no plausible
mechanism by which such an interaction between sam-
ple and assay type could occur, but acknowledge that
both the performance characteristics of the various as-
says, as well as the properties of the samples being
tested, may influence the results obtained in a small test-
ing population. In addition, samples that were most
often insufficiently stained by participating laboratories
are less prevalent in the general population (two of five
samples [40 %] in the NordiQC array were IHC 2+,
compared with a prevalence of such tumour types in the
population of approximately 12 %). We allowed for this
by weighting the results accordingly [19]. In addition,
our calculations are based on comparing hypothetical
situations in which laboratories either all use approved
IVD tests or all use laboratory-developed IVD tests,
whereas the reality is that a relatively small proportion
of participating laboratories use laboratory-developed
IVD tests. The proportion using laboratory-developed
IVD tests may be significantly higher in laboratories not
participating in proficiency programmes, however. Fi-
nally, this analysis was based on an economic analysis
with the assumptions and estimations inherent in such
models. Our intention was to provide an estimate of the
potential costs of using laboratory-developed IVD tests
and our results should therefore be considered as being
indicative rather than absolute.
Conclusions
The results of the present study demonstrate that the ac-
curacy of HER2 testing has far-reaching economic, so-
cioeconomic and clinical consequences that need to be
considered when a test is requested. Oncologists should
be aware that, although HER2-testing methodologies are
now numerous, significant differences exist between the
various available tests, which may impact on patient safety
as well as outcomes. As demonstrated by the NordiQC ex-
perience [15], both the approved and laboratory-developed
IVD tests can perform well and both can fail; nonetheless,
the degree of regulation applied to the approved IVDs re-
duces the risk of failure with these agents. Adherence to
testing guidelines would be expected to reassure the on-
cologist that accurate results can be obtained and that pa-
tients are subsequently treated correctly and not subjected
to the risks associated with inappropriate therapy.
We propose that diagnostic tests impacting directly on
treatment decisions, ie companion diagnostics, should
be subject to in-depth regulatory scrutiny in order to en-
sure that all patients receive appropriate treatment. It is
equally important that treatments are not incorrectly
prescribed, as many recently developed agents can be
very costly and may have undesired effects if used to
treat the wrong patients. It is vital that the accuracy and
reliability of companion diagnostic tests be maximised
and that the cut-offs are validated, ideally in clinical tri-
als or at least in prespecified analyses of retrospective
samples from prospectively conducted clinical trials.
Only with this level of scrutiny will patients receive the
appropriate treatment and benefit from the treatment
advances made in recent years.
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